Tresiba (insulin degludec) NDC 50090-3491

Product information

Brand name (proprietary)

Tresiba

Generic name (nonproprietary)

insulin degludec

Active ingredients

Insulin degludec — 200 U/mL

Dosage form

Injection, Solution

Route

Subcutaneous

Labeler

A-S Medication Solutions

Product type

Prescription drug

Marketing category

BLA — Biologics License ApplicationApplication BLA 203314

Marketing start

Sep 25, 2015

Listing expires

Dec 31, 2026

Other FDA classes

Insulin (Chemical structure)

Identifiers

Product ID 50090-3491_ee96b54f-5204-4b1b-8e9c-593f56045b66SPL ID ee96b54f-5204-4b1b-8e9c-593f56045b66SPL set ID 84197351-cb71-4282-8217-13103404a2b4RxCUI 1670021, 1670023UNII 54Q18076QB

Pharmacologic class

Insulin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N450090349100 followed by a unit qualifier and the quantity Copy

Package 50090-3491-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Other NDCs under BLA 203314

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.